The secondary efficacy end points were laboratory-measured fasting serum glucose (FSG) and insulin doses after 12 weeks of treatment;

• 第二功效研究终点是12周治疗后的实验室测量禁食血清葡萄糖(FSG)和胰岛素剂量；